Fusion Pharmaceuticals Inc. (NASDAQ: FUSN – Get a rating) was the target of a significant decline in short interest during the month of May. As of May 31, there was short interest totaling 30,300 shares, down 62.5% from the May 15 total of 80,800 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume of 14,600 shares, the short interest ratio is currently 2.1 days.
Separately, Wedbush cut its price target on Fusion Pharmaceuticals shares from $20.00 to $19.00 and set an “outperform” rating on the stock in a Tuesday, May 10 report.
NASDAQ: FUSN opened at $3.70 on Friday. Fusion Pharmaceuticals has a 1-year low of $3.41 and a 1-year high of $10.40. The company has a market capitalization of $160.37 million, a P/E ratio of -1.91 and a beta of -0.59. The company’s fifty-day moving average price is $4.91 and its two-hundred-day moving average price is $6.04.
Fusion Pharmaceuticals (NASDAQ: FUSN – Get a rating) last announced its results on Tuesday, May 10. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($0.50) by $0.04. The company posted revenue of $0.59 million in the quarter, compared to $4.50 million expected by analysts. Fusion Pharmaceuticals had a negative net margin of 4,119.85% and a negative return on equity of 34.87%. On average, equity research analysts expect Fusion Pharmaceuticals to post -2.1 earnings per share for the current year.
In related news, CEO John Valiant sold 4,511 shares of the company in a trade on Wednesday, April 27. The shares were sold at an average price of $6.03, for a total transaction of $27,201.33. As a result of the transaction, the CEO now directly owns 318,147 shares of the company, valued at $1,918,426.41. The sale was disclosed in a filing with the SEC, which is available via this link. In the past 90 days, insiders have sold 35,334 shares of the company worth $241,861. 6.12% of the shares are held by insiders.
Institutional investors have recently changed their positions in the company. Goldman Sachs Group Inc. increased its position in shares of Fusion Pharmaceuticals by 10.6% in the third quarter. Goldman Sachs Group Inc. now owns 20,149 shares of the company valued at $160,000 after acquiring an additional 1,928 shares during the period. UBS Group AG increased its position in shares of Fusion Pharmaceuticals by 45,219.1% in the first quarter. UBS Group AG now owns 21,300 shares of the company valued at $165,000 after acquiring an additional 21,253 shares during the period. Geode Capital Management LLC increased its position in Fusion Pharmaceuticals by 8.9% during the third quarter. Geode Capital Management LLC now owns 25,136 shares of the company worth $199,000 after purchasing an additional 2,047 shares during the period. Millennium Management LLC purchased a new stake in Fusion Pharmaceuticals during the third quarter valued at approximately $213,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Fusion Pharmaceuticals during the fourth quarter worth approximately $417,000. 64.25% of the shares are held by institutional investors.
Fusion Pharmaceuticals Company Profile (Get a rating)
Fusion Pharmaceuticals Inc, a clinical-stage oncology company, is focused on the development of radiopharmaceuticals as precision medicines. The company has developed the Targeted Alpha Therapies platform with its proprietary Fast-Clear linkage technology to allow us to connect alpha particle-emitting isotopes to various targeting molecules to selectively deliver alpha particle payloads to tumors. .
Get news and reviews for Fusion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily newsletter.